HLS vs. WEED, GUD, ACB, CPH, OGI, SUGR, FIRE, EPI, ICC, and RIV
Should you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Canopy Growth (WEED), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Cipher Pharmaceuticals (CPH), Organigram (OGI), SugarBud Craft Growers (SUGR), Supreme Cannabis (FIRE), ESSA Pharma (EPI), ICC Labs (ICC), and RIV Capital (RIV). These companies are all part of the "drug manufacturers - specialty & generic" industry.
HLS Therapeutics vs. Its Competitors
HLS Therapeutics (TSE:HLS) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.
In the previous week, Canopy Growth had 4 more articles in the media than HLS Therapeutics. MarketBeat recorded 5 mentions for Canopy Growth and 1 mentions for HLS Therapeutics. Canopy Growth's average media sentiment score of 0.95 beat HLS Therapeutics' score of 0.23 indicating that Canopy Growth is being referred to more favorably in the news media.
HLS Therapeutics has higher earnings, but lower revenue than Canopy Growth. HLS Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
HLS Therapeutics has a net margin of -38.70% compared to Canopy Growth's net margin of -201.27%. HLS Therapeutics' return on equity of -25.27% beat Canopy Growth's return on equity.
0.4% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Canopy Growth shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by insiders. Comparatively, 0.2% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
HLS Therapeutics has a beta of 0.48525, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 2.633279, meaning that its share price is 163% more volatile than the S&P 500.
HLS Therapeutics currently has a consensus price target of C$5.00, indicating a potential downside of 9.42%. Canopy Growth has a consensus price target of C$1.55, indicating a potential downside of 18.85%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe HLS Therapeutics is more favorable than Canopy Growth.
Summary
HLS Therapeutics beats Canopy Growth on 9 of the 15 factors compared between the two stocks.
Get HLS Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HLS Therapeutics Competitors List
Related Companies and Tools
This page (TSE:HLS) was last updated on 10/15/2025 by MarketBeat.com Staff
